Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy

International Journal of Urology

Volumn 12, Issue 12, 2005, Pages 1050-1054

  Nakamura, Masafumi ^a   Hasumi, Hisashi ^a   Miyoshi, Yasuhide ^a   Sugiura, Shinpei ^a   Fujinami, Kiyoshi ^a   Yao, Masahiro ^a   Kubota, Yoshinobu ^a   Uemura, Hiroji ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Prostate cancer; PSA nadir; Radical prostatectomy; Ultrasensitive PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RECURRENCE; CHEMICAL ANALYSIS; CONTROLLED STUDY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; EARLY DIAGNOSIS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE;

EID: 30944439248     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2005.01202.x     Document Type: Article

References (18)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J. Clin. 2004; 54: 8-29.
2. Statistics and Information Department. Minister's Secretariat, Ministry of Health, Labour and Welfare. Vital Statistics of Japan, 2001.
3. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol. 1994; 152: 1850-7.
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7.Z
5. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J. Urol. 2002; 167: 528-34.
6. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J. Urol. 2003; 170: 1872-6.
7. Grossfeld GD, Chang JJ, Broering JM et al. Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaP-SURE database. J. Urol. 2000; 163: 1171-7.
8. Shekarriz B, Upadhyay J, Bianco FJ Jr et al. Impact of preoperative serum PSA level from 0 to 10 ng/ml on pathological findings and disease-free survival after radical prostatectomy. Prostate 2001; 48: 136-43.
9. Kausik SJ, Blute ML, Sebo TJ et al. Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy. Cancer 2002; 95: 1215-19.
10. Egawa S, Matsui Y, Matsumoto K et al. Impact of biochemical failure on long-term clinical outcome after radical prostatectomy for prostate cancer in Japan. Prostate Cancer Prostatic Dis. 2004; 7: 152-7.
11. Japanese Urological Association, The Japanese Society of Pathology. General Rule for Clinical and Pathological Studies on Prostate Cancer, 3rd ed. Kanehara Publishing, Tokyo, 2001.
12. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-51.
13. Yu H, Diamandis EP, Wong PY, Nam R, Trachtenberg J. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L. J. Urol. 1997; 157: 913-18.
14. Arai Y, Okubo K, Aoki Y, Maekawa S, Okada T, Maeda H. Ultrasensitive assay of prostate-specific antigen for early detection of residual cancer after radical prostatectomy. Int. J. Urol. 1998; 5: 550-5.
15. Haese A, Huland E, Graefen M, Hammerer P, Noldus J, Huland H. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy. J. Urol. 1999; 161: 1206-11.
16. Doherty AP, Bower M, Smith GL et al. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br. J. Cancer 2000; 83: 1432-6.
17. Tanaka N. Clinical usefulness of high sensitive PSA with endocrine treatment in the prostate cancer. Nippon Hinyokika Gakkai Zasshi 2002; 93: 602-607.
18. Egawa S, Ohori M, Iwamura M, Kuwao S, Baba S. Efficacy and limitations of delayed/salvage radiation therapy after radical prostatectomy. BJU Int. 1999; 84: 815-20.